Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Who’s Who On The Joint Select Committee On Deficit Reduction

Executive Summary

The Budget Control Act created a 12-member bicameral panel charged with finding at least $1.2 trillion to cut from federal spending. The top Democrat and top Republican in each chamber of Congress appointed three members to serve on the joint committee. The Committee needs to make its legislative proposal by Thanksgiving, with only a simple majority needed to send the fiscal package to both chambers for approval. President Obama would then have to sign the bill by Jan. 15, 2012. A failure to accomplish this will trigger automatic spending cuts across all government programs as defined by the BCA (“Beware The Debt Deal’s Spending Cut Trigger: Medicare Part D and B Provider Pay Would Drop,” “The Pink Sheet” DAILY, Aug. 2, 2011). Health care related issues are expected to be a significant part of the discussions within the committee, including Medicaid-level rebates for drugs used by dual eligibles in the Medicare Part D program.

Related Content

OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings
Medicaid Gets Higher Rebates For Brand Drugs Compared To Medicare Part D, OIG Says
Beware The Debt Deal's Spending Cut Trigger: Medicare Part D And B Provider Pay Would Drop
Beware The Debt Deal's Spending Cut Trigger: Medicare Part D And B Provider Pay Would Drop
Hearings Show IPAB Has Little Support In House, But Does It Matter?
Could PhRMA Be Headed To The Energy And Commerce Committee Hot Seat For Reform Law Compromises?
Fiscal Commission's Final Plan Includes Rebates On Drugs Used By Medicare/Medicaid Dual Eligibles
PhRMA May Find Staunch Health Reform Opponent, But Part D Friend, In Ways And Means Chair
Dems Play “Choice” Card To Support Public Plan Option In House Budget Cmte.
International Rx Pricing Debate Plays Out In U.S./Australia Trade Negotiations





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts